Intraobserver | Interobserver | |||||||
Prevalence % (min–max) | Observed agreement (min–max) | Kappa range (min–max) (y/n) + 95% CI | Kappa range (min–max) (0–3) + 95% CI | Prevalence % (mean) | Observed agreement (mean) | Mean kappa (y/n) + 95% CI | Mean kappa (0–3) + 95% CI | |
SH | Grade 0: 9–34 | 0.31–0.94 | −0.01–0.94 (−0.31–0.31 to 0.82–1) | 0.06–0.96 (−0.42–0.27 to 0.9–1) | Grade 0: 22 | 0.76 | 0.57 (0.35 to 0.57) | 0.78 (0.54 to 0.78) |
Grade 1: 11–33 | Grade 1: 21 | |||||||
Grade 2: 8–47 | Grade 2: 35 | |||||||
Grade 3: 38–67 | Grade 3: 23 | |||||||
PD | Grade 0: 59–71 | 0.5–1 | −0.03–1.0 (−0.34–0.29 to 0.77–1) | 0.01–1.0 (−0.28–0.26 to 1–1) | Grade 0: 66 | 0.88 | 0.97 (0.8 to 0.97) | 0.98 (0.80 to 0.98) |
Grade 1: 4–15 | Grade 1: 10 | |||||||
Grade 2: 11–9 | Grade 2: 15 | |||||||
Grade 3: 5–14 | Grade 3: 9 | |||||||
Combined score* (SH+PD) | Grade 0: 13–70 | 0.39–1 | −0.01–1.0 (−0.24–0.4 to 1–1) | 0.06–1.0 (−0.0–0.4 to 1–1) | Grade 0: 32 | 0.81 | 0.80 (0.51 to 0.80) | 0.79 (0.57 to 0.79) |
Grade 1: 4–60 | Grade 1: 20 | |||||||
Grade 2: 8–45 | Grade 2: 28 | |||||||
Grade 3: 6–67 | Grade 3: 20 |
*EULAR-OMERACT combined score.
EULAR-OMERACT, European League Against Rheumatisms–Outcomes Measures in Rheumatology; PD, power Doppler; SH, synovial hypertrophy.